Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas*

We have previously demonstrated the effectiveness of adenovirus-mediated expression of antisense urokinase-type plasminogen activator receptor (uPAR) and matrix metalloproteinase-9 (MMP-9) in inhibiting tumor invasion in vitro and ex vivo. However, the therapeutic effect of the adenovirus-mediated antisense approach was shown to be transient and required potentially toxic, high viral doses. In contrast, RNA interference (RNAi)-mediated gene targeting may be superior to the traditional antisense approach, because the target mRNA is completely degraded and the molar ratio of siRNA required to degrade the target mRNA is very low. Here, we have examined the siRNA-mediated target RNA degradation of uPAR and MMP-9 in human glioma cell lines. Using RNAi directed toward uPAR and MMP-9, we achieved specific inhibition of uPAR and MMP-9. This bicistronic construct (pUM) inhibited the formation of capillary-like structures in both in vitro and in vivo models of angiogenesis. We demonstrated that blocking the expression of these genes results in significant inhibition of glioma tumor invasion in Matrigel and spheroid invasion assay models. RNAi for uPAR and MMP-9 inhibited cell proliferation, and significantly reduced the levels of phosphorylated forms of MAPK, ERK, and AKT signaling pathway molecules when compared with parental and empty vector/scrambled vector-transfected SNB19 cells. Furthermore, using RNAi to simultaneously target two proteases resulted in total regression of pre-established intracerebral tumor growth. Our results provide evidence that the use of hairpin siRNA expression vectors for uPAR and MMP-9 may provide an effective tool for cancer therapy.

[1]  Kyung-Hee Lee,et al.  Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4 , 2004, Experimental & Molecular Medicine.

[2]  D. Trisciuoglio,et al.  bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation , 2004, Journal of Biological Chemistry.

[3]  B. Cullen,et al.  Nuclear mRNA export: insights from virology. , 2003, Trends in biochemical sciences.

[4]  J. Rakic,et al.  Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[5]  T. Tamaya,et al.  Effects of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  M. Jo,et al.  Epidermal Growth Factor Receptor-dependent and -independent Cell-signaling Pathways Originating from the Urokinase Receptor* , 2003, The Journal of Biological Chemistry.

[7]  G. Kouraklis,et al.  Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion , 2002, Oncogene.

[8]  S. Park,et al.  PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. , 2002, Cancer research.

[9]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[10]  T. Cloughesy,et al.  Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  C. Gondi,et al.  Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro , 2002, Oncogene.

[12]  Patrick J. Paddison,et al.  RNA interference: the new somatic cell genetics? , 2002, Cancer cell.

[13]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[14]  K. Taira,et al.  U6 promoter–driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells , 2002, Nature Biotechnology.

[15]  T. Tuschl,et al.  Analysis of gene function in somatic mammalian cells using small interfering RNAs. , 2002, Methods.

[16]  G. Kouraklis,et al.  Down-regulation of Integrin αvβ3 Expression and Integrin-mediated Signaling in Glioma Cells by Adenovirus-mediated Transfer of Antisense Urokinase-type Plasminogen Activator Receptor (uPAR) and Sense p16 Genes* , 2001, The Journal of Biological Chemistry.

[17]  Jun Yao,et al.  Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-β1 in human breast cancer cells , 2001, Oncogene.

[18]  A. Fire,et al.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[20]  S. Müller,et al.  The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001, The Journal of cell biology.

[21]  P. Sharp,et al.  RNA interference--2001. , 2001, Genes & development.

[22]  G. Fuller,et al.  Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. , 2000, Cancer research.

[23]  S. Mohanam,et al.  A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas. , 2000, International journal of oncology.

[24]  R. Mohan,et al.  Modulation of TNF-α-induced apoptosis in corneal fibroblasts by transcription factor NF-κB , 2000 .

[25]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[26]  G. Nicolson,et al.  Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells , 1999, Clinical & Experimental Metastasis.

[27]  J. Roth,et al.  Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. , 1999, Cancer research.

[28]  A. H. Drummond,et al.  Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.

[29]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[30]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[31]  L. Ding,et al.  Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.

[32]  J. Uhm,et al.  Elevated levels of M(r) 92,000 type IV collagenase during tumor growth in vivo , 1998 .

[33]  Hua Tang,et al.  The Urokinase-type Plasminogen Activator Receptor Mediates Tyrosine Phosphorylation of Focal Adhesion Proteins and Activation of Mitogen-activated Protein Kinase in Cultured Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[34]  F. Hucho,et al.  Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. , 1998, European journal of biochemistry.

[35]  S. L. Gonias,et al.  Binding of Urokinase-type Plasminogen Activator to Its Receptor in MCF-7 Cells Activates Extracellular Signal-regulated Kinase 1 and 2 Which Is Required for Increased Cellular Motility* , 1998, The Journal of Biological Chemistry.

[36]  D. Boyd,et al.  Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. , 1998, Cancer research.

[37]  O. Mayboroda,et al.  The Jak/Stat Pathway and Urokinase Receptor Signaling in Human Aortic Vascular Smooth Muscle Cells* , 1998, The Journal of Biological Chemistry.

[38]  Z. Gokaslan,et al.  Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors , 1997, Clinical & Experimental Metastasis.

[39]  L. Zanetta,et al.  Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.

[40]  M. Moses The Regulation of Neovascularization by Matrix Metalloproteinases and Their Inhibitors , 1997 .

[41]  Z. Gokaslan,et al.  In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor , 1997, Oncogene.

[42]  R. Rappuoli,et al.  Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop , 1997, Infection and immunity.

[43]  B. Toole,et al.  Expression of multiple CD44 isoforms in the apical ectodermal ridge of the embryonic mouse limb , 1996, Developmental dynamics : an official publication of the American Association of Anatomists.

[44]  M. Westphal,et al.  Glioma invasion in the central nervous system. , 1996, Neurosurgery.

[45]  J. Bruner,et al.  Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. , 1994, Cancer research.

[46]  L. Liotta,et al.  Elevated Levels of Mr 92,000 Type IV Collagenase in Human Brain Tumors , 1993 .

[47]  J. Carmichael,et al.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[48]  K. Danø,et al.  Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. , 1993, The Journal of biological chemistry.

[49]  R. Jain,et al.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. , 1992, Cancer research.

[50]  M. Laiho,et al.  Growth factors in the regulation of pericellular proteolysis: a review. , 1989, Cancer research.

[51]  M. Kuwano,et al.  Up-regulation of Urokinase-type Plasminogen Activator and its Receptor Correlates with Enhanced Invasion Activity of Human Glioma Cells Mediated by Transforming Growth Factor-α or Basic Fibroblast Growth Factor , 2004, Journal of Neuro-Oncology.

[52]  W. Yung,et al.  Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades , 2004, Clinical & Experimental Metastasis.

[53]  B. Cullen,et al.  Sequence requirements for micro RNA processing and function in human cells. , 2003, RNA.

[54]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.